Karpouza Vassiliki
Research Subjects
Karpouza Vassiliki has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Aikaterini Arvaniti
Department of Psychiatry, Democritus University of Thrace, Alexandroupoli, Greece
1 shared publication - Alexandros Chaidemenos
Psychiatric Hospital of Athens, Athens, Greece
1 shared publication - Anastasia Zissi
Department of Sociology, University of the Aegean, Lesvos, Greece
1 shared publication - Anastasopoulos Odysseas
School of Psychology, Aristotle University of Thessaloniki, Thessaloniki, Greece
1 shared publication Bozikas Vasileios Panteleimon
1 shared publication- Charles Piwko
10Pivina Consulting Inc, Mississauga, Canada
1 shared publication
Latest Publications
- 13 August 2022
- Published by Springer Nature in Current Psychology
- Vol. 42 (28) , 24972-24985
What renders living alone a risk factor for involuntary psychiatric admission?
- 13 August 2022
- Published by Springer Nature in Current Psychology
- Vol. 42 (28) , 24972-24985
What renders living alone a risk factor for involuntary psychiatric admission?
- Open Access
- 1 January 2012
- Published by Springer Nature in Annals of General Psychiatry
- Vol. 11 (1) , 18
Pharmacoeconomic analysis of paliperidone palmitate for treating schizophrenia in Greece
Patients having chronic schizophrenia with frequent relapses and hospitalizations represent a great challenge, both clinically and financially. Risperidone long-acting injection (RIS-LAI) has been the main LAI atypical antipsychotic treatment in Greece. Paliperidone palmitate (PP-LAI) has recently been approved. It is dosed monthly, as opposed to biweekly for RIS-LAI, but such advantages have not yet been analysed in terms of economic evaluation.
- 1 January 2012
- Published by Springer Nature in Annals of General Psychiatry
- Vol. 11 (1) , 18
Open AccessPharmacoeconomic analysis of paliperidone palmitate for treating schizophrenia in Greece
Patients having chronic schizophrenia with frequent relapses and hospitalizations represent a great challenge, both clinically and financially. Risperidone long-acting injection (RIS-LAI) has been the main LAI atypical antipsychotic treatment in Greece. Paliperidone palmitate (PP-LAI) has recently been approved. It is dosed monthly, as opposed to biweekly for RIS-LAI, but such advantages have not yet been analysed in terms of economic evaluation.